{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:56:20Z","timestamp":1774403780060,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00259-025-07631-2","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:54:32Z","timestamp":1763020472000},"page":"2963-2973","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relationship between [18F]PSMA-1007 PET parameters and biochemical recurrence-free survival in high-risk prostate cancer patients receiving neoadjuvant hormonal treatment"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-0161","authenticated-orcid":false,"given":"Niloefar","family":"Ahmadi Bidakhvidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3345-4573","authenticated-orcid":false,"given":"Alexander","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6772-915X","authenticated-orcid":false,"given":"Ga\u00ebtan","family":"Devos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-442X","authenticated-orcid":false,"given":"Annouschka","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0882-2944","authenticated-orcid":false,"given":"Marcella","family":"Baldewijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5862-640X","authenticated-orcid":false,"given":"Michel","family":"Koole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-1577","authenticated-orcid":false,"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3157-7115","authenticated-orcid":false,"given":"Wouter","family":"Everaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3195-9890","authenticated-orcid":false,"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7453-0229","authenticated-orcid":false,"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"7631_CR1","unstructured":"Mottet NvdBR, Briers E, Bourke L, Cornford P, et al. Eau-Estro-Esur-Siog guidelines on prostate cancer. arnhem, the Netherlands: European Association of Urology. 2023."},{"key":"7631_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40336-023-00582-4","volume":"12","author":"P Claes","year":"2024","unstructured":"Claes P, Ahmadi Bidakhvidi N, Giesen A, Joniau S, Van Laere K, Koole M, et al. PSMA PET\/CT and PET\/MRI in primary staging of prostate cancer and its effect on patient management. Clin Translational Imaging. 2024;12:31\u201354.","journal-title":"Clin Translational Imaging"},{"key":"7631_CR3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00330-021-08140-0","volume":"32","author":"S Jentjens","year":"2022","unstructured":"Jentjens S, Mai C, Ahmadi Bidakhvidi N, De Coster L, Mertens N, Koole M, et al. Prospective comparison of simultaneous [(68)Ga]Ga-PSMA-11 PET\/MR versus PET\/CT in patients with biochemically recurrent prostate cancer. Eur Radiol. 2022;32:901\u201311. https:\/\/doi.org\/10.1007\/s00330-021-08140-0.","journal-title":"Eur Radiol"},{"key":"7631_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4103\/aja.aja_96_20","volume":"23","author":"W Liu","year":"2021","unstructured":"Liu W, Yao Y, Liu X, Liu Y, Zhang GM. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2021;23:429\u201336. https:\/\/doi.org\/10.4103\/aja.aja_96_20.","journal-title":"Asian J Androl"},{"key":"7631_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","volume":"83","author":"G Devos","year":"2023","unstructured":"Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V, et al. Arneo: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer. Eur Urol. 2023;83:508\u201318. https:\/\/doi.org\/10.1016\/j.eururo.2022.09.009.","journal-title":"Eur Urol"},{"key":"7631_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-019-04581-4","volume":"47","author":"C Onal","year":"2020","unstructured":"Onal C, Guler OC, Torun N, Reyhan M, Yapar AF. The effect of androgen deprivation therapy on (68)Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:632\u201341. https:\/\/doi.org\/10.1007\/s00259-019-04581-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7631_CR7","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000001481","volume":"205","author":"M Chen","year":"2021","unstructured":"Chen M, Zhuang J, Fu Y, Guo S, Zang S, Ai S, et al. Can (68)Ga-PSMA-11 positron emission tomography\/Computerized tomography predict pathological response of primary prostate cancer to neoadjuvant androgen deprivation therapy? A pilot study. J Urol. 2021;205:1082\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000001481.","journal-title":"J Urol"},{"key":"7631_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/pros.24553","volume":"83","author":"X Du","year":"2023","unstructured":"Du X, Dong Y, Liu J, Su Y, Zhu Y, Pan J, et al. Baseline PSMA-PET\/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy. Prostate. 2023;83:1112\u201320. https:\/\/doi.org\/10.1002\/pros.24553.","journal-title":"Prostate"},{"key":"7631_CR9","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s00259-022-06047-6","volume":"50","author":"ZB Ke","year":"2023","unstructured":"Ke ZB, Chen SM, Chen JY, Chen SH, You Q, Sun JB, et al. Head-to-head comparisons of [(68)Ga]Ga-PSMA-11 PET\/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study. Eur J Nucl Med Mol Imaging. 2023;50:1240\u201351. https:\/\/doi.org\/10.1007\/s00259-022-06047-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7631_CR10","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2967\/jnumed.122.265368","volume":"64","author":"M Chen","year":"2023","unstructured":"Chen M, Fu Y, Peng S, Zang S, Ai S, Zhuang J, et al. The association between [(68)Ga]PSMA PET\/CT response and biochemical progression in patients with High-Risk prostate cancer receiving neoadjuvant therapy. J Nucl Med. 2023;64:1550\u20135. https:\/\/doi.org\/10.2967\/jnumed.122.265368.","journal-title":"J Nucl Med"},{"key":"7631_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph10040077","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Martin R, Remde Y, Schafer M, Hienzsch A, Hubner S, et al. Procedures for the GMP-compliant production and quality control of [(18)F]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer. Pharmaceuticals (Basel). 2017. https:\/\/doi.org\/10.3390\/ph10040077.","journal-title":"Pharmaceuticals (Basel)"},{"key":"7631_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"key":"7631_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s13139-018-0548-3","volume":"52","author":"M Gupta","year":"2018","unstructured":"Gupta M, Choudhury PS, Rawal S, Goel HC, Rao SA. Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study. Nucl Med Mol Imaging. 2018;52:420\u20139. https:\/\/doi.org\/10.1007\/s13139-018-0548-3.","journal-title":"Nucl Med Mol Imaging"},{"key":"7631_CR14","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/jnumed.121.263072","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic Castration-Resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63:1651\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263072.","journal-title":"J Nucl Med"},{"key":"7631_CR15","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1007\/s00259-023-06321-1","volume":"50","author":"C Onal","year":"2023","unstructured":"Onal C, Guler OC, Torun N, Oymak E, Reyhan M. The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [(68)Ga]Ga-PSMA-11-PET\/CT in high-risk prostate cancer patients treated with definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2023;50:3755\u201364. https:\/\/doi.org\/10.1007\/s00259-023-06321-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7631_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:9\u201315. https:\/\/doi.org\/10.1007\/s00259-019-04529-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7631_CR17","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.23.00617","volume":"41","author":"S Roy","year":"2023","unstructured":"Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, et al. Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate. J Clin Oncol. 2023;41:5005\u201314. https:\/\/doi.org\/10.1200\/JCO.23.00617.","journal-title":"J Clin Oncol"},{"key":"7631_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06903-7","author":"N Ahmadi Bidakhvidi","year":"2024","unstructured":"Ahmadi Bidakhvidi N, Gevaert T, De Schepper M, Baldewijns M, Havinga E, Deckers W, et al. Comparison of PSMA immunohistochemistry scoring systems to parametric [(18)F]PSMA-1007 PET\/MRI in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06903-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7631_CR19","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07631-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07631-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07631-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:01Z","timestamp":1774401961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07631-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7631"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07631-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christophe M. Deroose is\/has been a consultant for (fees received by institution): Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO, Immedica Pharma, Molecular Partners, Nuclear Research and consultancy. His institution has received travel fees from: GE Healthcare, Sirtex. Karolien Goffin is\/has been a consultant for (fees received by institution): Novartis, Bayer, Telix, PSI CRO, Full-Life Technologies, Blue Earth Theranostics, MSK. Her institution has received travel fees from: GE Healthcare, Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee Research UZ\/KU Leuven (EC Research; study number S58827) and complied with the declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and to publish"}}]}}